Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew B Lassman

Showing results (81-90 of 145) with videos related to

Pageof 15
Sort By:
Journal of Neuro-Oncology|December 22, 2017
Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastomaDeborah R Smith, Cheng-Chia Wu, Heva J Saadatmand, et al.
Neurosurgery|October 7, 2015
Timing of Adjuvant Radiotherapy in Glioblastoma Patients: A Single-Institution Experience With More Than 400 PatientsTony J C Wang, Ashish Jani, Juan P Estrada, et al.
Neuro-Oncology|April 26, 2015
Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?Tony J C Wang, Shumaila Saad, Yasir H Qureshi, et al.
Neuro-Oncology|January 8, 2023
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survivalBenjamin M Ellingson, Patrick Y Wen, Susan M Chang, et al.
Neuro-Oncology|August 8, 2014
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningiomaThomas J Kaley, Patrick Wen, David Schiff, et al.
Journal of Neuro-Oncology|November 29, 2019
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastomaMartin van den Bent, Analia Azaro, Filip De Vos, et al.
Journal of Neuro-Oncology|November 25, 2017
Local control and overall survival for adjuvant stereotactic radiosurgery in patients with residual or recurrent diseaseTavish Nanda, Andrew Yaeh, Cheng-Chia Wu, et al.
Neuro-Oncology|December 18, 2012
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant gliomaAntonio Omuro, Timothy A Chan, Lauren E Abrey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2019
Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with GlioblastomaAndrew B Lassman, Lisa Roberts-Rapp, Irina Sokolova, et al.
Neuro-Oncology|January 1, 2017
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastomaDavid A Reardon, Andrew B Lassman, Martin van den Bent, et al.
Pageof 15

Showing results (81-90 of 145) with videos related to

Sort By:
Pageof 15
Journal of Neuro-Oncology|December 22, 2017
Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastomaDeborah R Smith, Cheng-Chia Wu, Heva J Saadatmand, et al.
Neurosurgery|October 7, 2015
Timing of Adjuvant Radiotherapy in Glioblastoma Patients: A Single-Institution Experience With More Than 400 PatientsTony J C Wang, Ashish Jani, Juan P Estrada, et al.
Neuro-Oncology|April 26, 2015
Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?Tony J C Wang, Shumaila Saad, Yasir H Qureshi, et al.
Neuro-Oncology|January 8, 2023
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survivalBenjamin M Ellingson, Patrick Y Wen, Susan M Chang, et al.
Neuro-Oncology|August 8, 2014
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningiomaThomas J Kaley, Patrick Wen, David Schiff, et al.
Journal of Neuro-Oncology|November 29, 2019
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastomaMartin van den Bent, Analia Azaro, Filip De Vos, et al.
Journal of Neuro-Oncology|November 25, 2017
Local control and overall survival for adjuvant stereotactic radiosurgery in patients with residual or recurrent diseaseTavish Nanda, Andrew Yaeh, Cheng-Chia Wu, et al.
Neuro-Oncology|December 18, 2012
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant gliomaAntonio Omuro, Timothy A Chan, Lauren E Abrey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2019
Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with GlioblastomaAndrew B Lassman, Lisa Roberts-Rapp, Irina Sokolova, et al.
Neuro-Oncology|January 1, 2017
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastomaDavid A Reardon, Andrew B Lassman, Martin van den Bent, et al.
Pageof 15